Company: SCYX
Filing Date: 2025-03-12
Form Type: 10-K
Source: 0000950170-25-038044
Chunk: 127

Company: SCYNEXIS INC
Filing Date: 2025-03-12
Form: 10-K
Item: Item 1B
Chunk 127
---
 (195
    )

    (135
    )

    Payments of loan payable

    —

    (36,383
    )

    Payment of loan payable prepayment fee

    —

    (263
    )

    Proceeds from employee stock purchase plan issuances

    56

    42

    Repurchase of shares to satisfy tax withholdings

    —

    18

    Net cash used in financing activities

    (139
    )

    (36,721
    )

    Net decrease in cash, cash equivalents, and restricted cash

    (17,998
    )

    (11,439
    )

    Cash, cash equivalents, and restricted cash at beginning of period

    34,593

    46,032

    Cash, cash equivalents, and restricted cash at end of period
     
    $
    16,595

    $
    34,593

    Supplemental cash flow information:

    Cash paid for interest
     
    $
    840

    $
    3,248

    Cash received for interest
     
    $
    3,296

    $
    3,520

    Noncash financing and investing activities:

    Deferred offering and issuance costs included in accounts payable
     
    $
    110

    $
    40

    Deferred offering costs reclassified to additional paid-in capital
     
    $
    —

    $
    73

The accompanying notes are an integral part of the financial statements.

62

SCYNEXIS, INC.

NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS

1.Description of Business and Basis of PreparationOrganizationSCYNEXIS, Inc. ("SCYNEXIS" or the “Company”) is a Delaware corporation formed on November 4, 1999. SCYNEXIS is a biotechnology company, headquartered in Jersey City, New Jersey, and is pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections.  The Company is developing its proprietary class of enfumafungin-derived antifungal compounds (“fungerps") as broad-spectrum, systemic antifungal agents for multiple fungal indications. Ibrexafungerp is the first representative of this novel class of antifungals with additional assets from the “fungerp” family under development, including SCY-247 which is currently in clinical stages of development.  In June 2021, the U.S. Food and Drug Administration (“FDA